Skip to main content
. Author manuscript; available in PMC: 2009 Jun 4.
Published in final edited form as: Immunity. 2007 Dec 27;28(1):122–133. doi: 10.1016/j.immuni.2007.11.017

Figure 4. PTX treatment facilitates egress of FTY720 exposed and S1P1 deficient cells.

Figure 4

(A) Egress of PTX or oligomer B treated T cells from lymph nodes of FTY720 treated mice. Splenocytes were treated with PTX or with Oligomer B (Oligo-B) as a control and co-transferred into hosts pre-treated with saline or FTY720 4 h earlier. Three hours after transfer, the mice were treated with integrin-blocking antibodies. The number of remaining cells in lymph nodes 21 h after “entry blockade” was determined. Numbers shown are normalized for the number of input splenocytes. (B and C) PTX restores egress of S1P1-deficient lymphocytes. (B) Diagram of transfer experiment. (C) Number of transferred Oligomer B or PTX treated Edg1-/- or Edg1+/+ T cells in peripheral lymph nodes and blood at 0 h and 27 h of integrin blockade. Numbers shown are normalized for the number of CD62L-high, single-positive input thymocytes. Bars represent mean and points individual animals.